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Endoglin is an homodimeric membrane antigen with capacity to
bind transforming growth factor-,f (TGF-,8). Phosphorylation of
human endoglin was demonstrated in endothelial cells as well as
in mouse fibroblast transfectants expressing two isoforms,
L-endoglin or S-endoglin, with distinct cytoplasmic domains.
The extent of L-endoglin phosphorylation was found to be 8-fold
higher than that of S-endoglin, and phosphopeptide analyses
INTRODUCTION
Endoglin, also known as 'CD 105' (Endothelial Section, Fifth
International Conference on Human Leukocyte Differentiation
Antigens, Boston, U.S.A., November 3-7, 1993), is a 180 kDa
homodimeric membrane glycoprotein expressed by human en-
dothelial cells [1], macrophages [2,3], erythroid precursors [4],
syncytiotrophoblasts of term placenta [5] and fibroblasts [1]. The
gene encoding endoglin has been localized to human chromosome
9 [6]. Recently it has been demonstrated that endoglin binds
TGF-fll and TGF-,83 with high affinity (KD 50 pM) in human
endothelial cells [7]. Two different isoforms, L-endoglin and S-
endoglin, with capacity to bind TGF-fl, but differing in the
amino acid composition of their cytoplasmic tails, have been
characterized [8,9]. /3-Glycan and endoglin belong to a class of
TGF-,J receptors (type III receptors) that may function as
regulators of TGF-f access to the signalling heteromeric kinase
receptor complex formed by TGF-,8 receptor components I and
II [10-12]. Interestingly, ,-glycan and the predominant isoform,
L-endoglin, share a region of high identity in the cytoplasmic tail
with a high content (40%) of Ser/Thr residues [8,13-15], which
suggests that this domain might undergo phosphorylation by a
Ser/Thr kinase. Here we have characterized the phosphorylation
of human endoglin.
MATERIALS AND METHODS
Cells
Human umbilical-vein endothelial cells (HUVEC) were isolated
from term umbilical-cord veins by collagenase perfusion as
described in [16]. HUVEC were maintained in RPMI medium
containing 20% (v/v) fetal-calf serum, 50 ,g/ml endothelial cell
growth supplement (Collaborative Research) and 100 jig/ml of
heparin (Sigma). Phosphorylation assays were performed using
cells at passages 2-4. Mouse fibroblast transfectants expressing
human L-endoglin or S-endoglin were generated by cotrans-
fection of full-length cDNA encoding L-endoglin or S-endoglin
in pcEXV and psV2neo [9]. After selection in RPMI medium
revealed at least three different phosphorylation sites for
L-endoglin, whereas S-endoglin produces only one phospho-
peptide. The immunoprecipitated L-endoglin was found to be
phosphorylated mainly on serine, and, to a minor extent, on
threonine, residues. Treatment of the cells with TGF-,81 or the
protein kinase C inhibitor H-7 resulted in a reduction of the
levels of endoglin phosphorylation.
containing 10% fetal-calf serum and 400 jug/ml of the antibiotic
G418 (Sigma), endoglin-positive clones were isolated by flow-
cytometry analysis. Endoglin-negative clones were selected as
mock transfectants. To remove the cells from the culture flasks,
HUVEC or mouse transfectant monolayers were treated with
trypsin for 3 min at room temperature and washed with RPMI
containing 100% fetal-calf serum at 4 'C.
Phosphorylatlon studies
Confluent monolayers ofHUVEC and transfectant mouse fibro-
blasts from 75 cm2 flasks were preincubated for 30 min at 37 'C
in phosphate-free RPMI medium containing dialysed 10%
fetal-calf serum. After preincubation, the medium was removed
and fresh medium containing 100 ,uCi/ml of [32P]orthophosphate
(ICN Biomedicals) was added. Cells were metabolically labelled
at 37 'C under a 5 %-CO2 atmosphere for 4 h. In some experi-
ments, labelling of endoglin transfectants with [32P]ortho-
phosphate was performed as described above, but in the presence
of 10 ng/ml of TGF-/Jl (British Biotechnology). Experiments
with the protein kinase C (PKC) inhibitor 1-(5-isoquinoline-
sulphonyl)-2-methylpiperazine (H-7) (Sigma) were carried out
by culturing the cells at 1O,tM or 100 ,tM of H7 for 30 min,
followed by the [32P]orthophosphate labelling, also in the pres-
ence of H7. At these concentrations, the viability of the cells was
over 95 %.
Metabolic labelling with [3S]methionine/cystelne
Confluent monolayers of transfectant mouse fibroblasts from
75 cm2 flasks were preincubated for 30 min at 37 °C in RPMI
methionine/cysteine-free medium containing dialysed 10% fetal-
calf serum. After preincubation, the medium was removed and
fresh medium, containing 100 guCi/ml of [35S]methionine/
cysteine (Trans35S-label; ICN Biomedicals), was added. Cells
were metabolically labelled for 14 h at 37 °C under a 5% CO2
atmosphere.
Abbreviations used: HUVEC, human umbilical-vein endothelial cells; TGF-fl, transforming growth factor-fl; PKC, protein kinase C; mAb, monoclonal
antibody.
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Figure 1 Phosphorylation of endoglin
(a) Immunoprecipitation analysis of endoglin in endothelial cells. Human endothelial cells were metabolically labelled with [32P]orthophosphate, lysed, and immunoprecipitated with 44G4 (anti-
endoglin), 8E1 1 (anti-endoglin) or HC1 /1 (anti-CDlic) mAb. The HC1/1 mAb was used as a negative control. Samples were subjected to SDS/PAGE and autoradiography. (b) Immunoprecipitation
analysis of L-endoglin and S-endoglin. Mouse fibroblast transfectants expressing either L-endoglin or S-endoglin were metabolically labelled with either [32P]orthophosphate or [35S]methionine,
lysed, and immunoprecipitated with 44G4 (anti-endoglin). Samples were subjected to SDS/PAGE and autoradiography. Bands of 170 kDa and 160 kDa corresponding to L-endoglin and S-endoglin
respectively are indicated. Open arrowheads (p) indicate an additional 100 kDa band specifically immunoprecipitated from L-endoglin transfectants. (c) Phosphopeptide analysis of endoglin
isoforms. L-endoglin (i) and S-endoglin (ii) were immunoprecipitated from [32P]orthophosphate-labelled transfectants and digested with the endoproteinase Glu-C from S. aureus and with the proline-
specific endopeptidase from F meningosepticum. Phosphopeptides were separated by high-voltage thin-layer electrophoresis. The origin of the samples and the separated peptides were indicated
by V and A respectively. (d) Phosphoamino acid analysis of L-endoglin immunoprecipitated from [32P]orthophosphate-labelled transfectants. S, phosphoserine; T, phosphothreonine; Y,
phosphotyrosine.
Immunoprecipitation studies
Metabolically labelled cells were lysed in PBS, pH 7.4, containing
10% Triton X-100, 1 mM phenylmethanesulphonyl fluoride,
1 mM orthovanadate, 1 mM sodium molybdate and 1 mM NaF
(lysis buffer) for 15 min at 4 'C. The lysates were centrifuged for
20 min at 12 000 g and pre-cleared for 2 h with protein G coupled
to Sepharose (Pharmacia Fine Chemicals, Uppsala, Sweden) at
4 'C. Specific immunoprecipitations of the pre-cleared lysates
were carried out in the presence of 10 ,ug/ml of the monoclonal
antibodies (mAb) 8E1 1 (anti-endoglin) of the IgM class [2], 44G4
(anti-endoglin) of the IgGI subclass [1] and HC1 / (anti-CD Ic)
of the IgGI subclass, using Protein G coupled to Sepharose [2].
After incubation at 4 'C for 4 h, immunoprecipitates were
isolated by centrifugation, washed twice with lysis buffer at 4 'C
and then subjected to SDS/PAGE on a 6 %-acrylamide gel
under non-reducing conditions, followed by autoradiography.
The amount of endoglin radiolabel was quantified with a
Phosphorlmager 410A and ImageQuant software (Molecular
Dynamics).
PhosphopeptWle analysis
32P-Labelled L-endoglin or S-endoglin were immunoprecipitated
from mouse transfectants and electrophoresed on a 6 %-acryla-
mide gel. Endoglin bands were localized by autoradiography, cut
out, and the protein was eluted from the gel as described in [18].
Proteolytic digestions were carried out first with endoproteinase
Glu-C from Staphylococcus aureus V8 (EC 3.4.21.19; Boehringer
Mannheim, Barcelona, Spain) in 0.1 M NH4HCO3, pH 7.4,
overnight at 37 °C, followed by incubation with the proline-
specific endopeptidase from Flavobacterium meningosepticum
(EC 3.4.21.26; ICN Biomedicals) in 0.1 M phosphate buffer,
pH 7.0, for 3 h at 30 'C. Phosphopeptides were separated by
thin-layer electrophoresis in 10 g/l of (NH4)2CO3, pH 8.9, for
30 min at 1 kV as described in [18]. Radiolabelled peptides were
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detected on the plate with a Phosphorlmager 410A and Image-
Quant software (Molecular Dynamics).
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Phosphoamino acid analysis
32P-labelled L-endoglin was immunoprecipitated from mouse
transfectants as described above, electrophoresed on a 6%-
acrylamide gel and electroblotted on to nylon membranes
(Hybond-N; Amersham International). The endoglin nylon band
localized by autoradiography was cut out and directly digested in
200 Ial of 6 M HCI at 110 °C for 4 h. Phosphoamino acids were
analysed by two-dimensional thin-layer electrophoresis as pre-
viously described [18].
Flow cytometry
Cells (5 x 105) were incubated with the mAb 44G4 at 10 ,tg/ml
for 30 min at 4 'C. After two washes with PBS containing 0.1 0%
BSA and 0.04% NaN3, fluorescein isothiocyanate-labelled
F(ab')2 rabbit anti-mouse IgG (Dakopatts) was added and
incubation proceeded for an additional period of 30 min at 4 °C.
Finally, cells were washed twice and their fluorescence was
estimated with an EPICS-CS instrument (Coulter Cientifica,
Mostoles, Spain) using logarithmic amplifiers.
RESULTS AND DISCUSSION
Human endoglin Is constitutively phosphorylated
To analyse the phosphorylation status of endoglin, we used
endothelial cells where endoglin is highly expressed [1]. These
cells were metabolically labelled with [32P]orthophosphate and
analysed by immunoprecipitation (Figure la). A phosphorylated
protein of 170 kDa was specifically immunoprecipitated with
two different monoclonal antibodies to endoglin. Recently, two
isoforms of endoglin with distinct cytoplasmic domains have
been identified [9]. The predominant form is L-endoglin, which
contains 47 amino acids in the cytoplasmic tail, rather than S-
endoglin, which has 14 residues. To analyse the phosphorylation
status of these isoforms, we carried out metabolic labelling of
mouse fibroblast transfectants expressing either L-endoglin or
S-endoglin. Immunoprecipitation studies revealed a heavily
phosphorylated 170 kDa band of L-endoglin, which contrasted
with a weakly labelled 160 kDa band corresponding to S-endoglin
(Figure lb). The phosphorylation of L-endoglin was found to be
approx. 8-fold greater than that of S-endoglin, suggesting the
existence of multiple phosphorylation sites in the long isoform.
This result is in agreement with the presence in the cytoplasmic
domain of 19 Ser/Thr residues in L-endoglin and 2 Ser/Thr
residues in S-endoglin. As a control, immunoprecipitations from
35S-labelled transfectants showed similar labelling of L-endoglin
and S-endoglin (Figure lb). On the other hand, a polypeptide of
approx. 100 kDa was specifically immunoprecipitated from 32p-
or 35S-labelled L-endoglin transfectants (>, Figure lb). It will be
of interest to analyse whether this band corresponds to a
heteromeric association with the type II receptor, as reported for
,8-glycan [11]. Further support for multiple phosphorylation sites
of L-endoglin was obtained by phosphopeptide analysis (Figure
lc). Thus digestions of the phosphorylated endoglin isoforms
with glutamine- and proline-specific proteinases revealed at least
three different phosphorylation sites for L-endoglin against only
one for S-endoglin.
Since L-endoglin is the predominant form of endoglin in
endothelial cells [9], we studied its phosphorylation in more
detail. Phosphoamino acid analysis of 32P-labelled L-endoglin
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Figure 2 Effect of TGF-pI and H-7 on endoglin phosphorylation
(a) Immunoprecipitation analysis. Mouse fibroblast transfectants expressing L-endoglin were
metabolically labelled with [32P]orthophosphate in either the absence or the presence of
TGF-,f1 (10 ng/ml) or the PKC inhibitor H-7 (10 ,uM or 100 ,uM). Cells were lysed, then
immunoprecipitated with 44G4 (anti-endoglin) mAb. Samples were subjected to SDS/PAGE and
autoradiography. The radioactivity associated with the endoglin bands was quantified in the
autoradiographs by using a Phosphorimager instrument (Molecular Dynamics), and the values
obtained were plotted as percentage of the amount present in the absence of treatment. The
results are means and S.D.s for three different experiments. Representative autoradiographs are
shown. (b) Flow-cytometric analysis. Mouse fibroblast transfectants expressing L-endoglin
were incubated in the absence or presence of TGF-fll (10 ng/ml) or the PKC inhibitor H-7
(100 uM) as described in the Materials and methods section. Then cells were stained for
indirect immunofluorescence with the mAb 44G4 (anti-endoglin). Control stainings of endoglin-
mock transfectants are also shown. Numbers at the upper-right corner indicate the mean
fluorescence intensity of the endoglin-positive transfectants. The broken vertical line represents
the limit of specific fluorescence. The result obtained at 10 ,uM H-7 was found to be similar
to that shown here at 100 mM H-7. This is a representative experiment of another two that gave
similar results.
indicated that serine, and to a minor extent threonine, residues
were phosphorylated (Figure ld). We could not detect any signal
corresponding to phosphotyrosine. Furthermore, no specific
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recognition of either L-endoglin or S-endoglin was achieved by
Western-blot analysis using an anti-phosphotyrosine antibody
(result not shown).
Effect of TGF-,B and the PKC inhibitor H7 on the phosphorylatlon
of endoglin
The signalling TGF-, receptor types I and II form a ligand-
induced heteromeric complex with fl-glycan [11] and have been
shown to contain serine/threonine kinase activities in their
intracellular domains [19,20]. To analyse whether the signalling
induced by TGF-,l affects phosphorylation of endoglin, we
carried out [32P]orthophosphate labelling in the presence of
ligand (Figure 2a). Addition of TGF-,ll was found to decrease
significantly the phosphorylation level of L-endoglin. As a
control, the level of endoglin surface expression was found to be
unaffected in the presence of TGF-,81 (Figure 2b), excluding a
ligand-induced internalization of endoglin. This inhibitory effect
on L-endoglin phosphorylation was reproduced in three different
experiments and was also observed with S-endoglin (results not
shown). Whether the mechanism of this TGF-/3l-induced in-
hibition of phosphorylation is shared with that reported for the
retinoblastoma protein [21] remains to be determined.
A computer search for consensus sequences ofphosphorylation
(Database PROSITE; GCG Software Genetics Computer
Group) revealed that the L-endoglin cytoplasmic domain con-
tains one potential phosphorylation site for PKC (serine-621;
RXXSKR). To analyse the possible involvement of this kinase,
we carried out phosphorylation studies in the presence of the
PKC inhibitor H-7 (Figure 2a). Addition of H-7 clearly inhibited
the phosphorylation of endoglin at two different concentrations,
whereas surface expression of endoglin was found to be unaf-
fected (Figure 2b).
The cytoplasmic domains of fl-glycan and L-endoglin are
highly conserved in human and rat [8,13-15], implying a common
important function for this domain. We find that human L-
endoglin is constitutively phosphorylated on serine and threonine
residues, suggesting a role in signalling and/or cytoplasmic
association with other proteins. Our results do not support a
TGF-,#-dependent participation by the Ser/Thr kinase activity of
the signalling receptors I and II, but they do not exclude their
involvement in the absence of ligand. Since the phosphorylation
of endoglin is detected in the absence of stimuli, it is probably
carried out by a 'housekeeping' kinase. In this sense the inhibition
of phosphorylation by H-7 suggests the involvement of PKC.
Given the existence of a large family of PKC isoforms [22], the
interaction of PKC with other signalling pathways and the
possible cross-inhibition by H-7 of other Ser/Thr kinases, more
detailed studies are required to identify the kinase/s responsible
for endoglin phosphorylation.
Note added in proof (received 26 May 1994)
While this manuscript was under review, Yamashita et al. [23]
reported that porcine endoglin is a phosphorylated protein which
forms a heteromeric complex with signalling TGF-, receptors.
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